Angiogenesis Inhibitors

"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Descriptor ID	D020533
MeSH Number(s)	D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
Concept/Terms	Angiogenesis Inhibitors Angiogenesis Inhibitors Neovascularization Inhibitors Angiogenic Antagonists Angiogenic Inhibitors Angiostatic Agents Agents, Angiostatic Antagonists, Angiogenic Anti-Angiogenetic Agents Agents, Anti-Angiogenetic Anti Angiogenetic Agents Anti-Angiogenic Drugs Anti Angiogenic Drugs Drugs, Anti-Angiogenic Antiangiogenic Agents Agents, Antiangiogenic Inhibitors, Angiogenesis Inhibitors, Angiogenetic Inhibitors, Angiogenic Inhibitors, Neovascularization Angiogenetic Antagonists Antagonists, Angiogenetic Angiogenetic Inhibitors Angiogenesis Factor Inhibitors Angiogenesis Factor Inhibitors Factor Inhibitors, Angiogenesis Inhibitors, Angiogenesis Factor Anti-Angiogenesis Effect Anti-Angiogenesis Effect Anti Angiogenesis Effect Effect, Anti-Angiogenesis Antiangiogenesis Effect Effect, Antiangiogenesis Antiangiogenesis Effects Effects, Antiangiogenesis Anti-Angiogenesis Effects Anti Angiogenesis Effects Effects, Anti-Angiogenesis

Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Growth Substances [D27.505.696.377]
Angiogenesis Modulating Agents [D27.505.696.377.077]
Angiogenesis Inhibitors [D27.505.696.377.077.099]
Growth Inhibitors [D27.505.696.377.450]
Angiogenesis Inhibitors [D27.505.696.377.450.100]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Angiogenesis Inhibitors [D27.505.954.248.025]

Below are MeSH descriptors whose meaning is related to "Angiogenesis Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.

Bar chart showing 47 publications over 16 distinct years, with a maximum of 7 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2004	2	2	4
2005	1	0	1
2008	1	1	2
2009	1	1	2
2010	1	0	1
2011	3	2	5
2012	2	1	3
2013	2	0	2
2014	3	2	5
2015	6	1	7
2016	3	3	6
2017	0	1	1
2018	1	0	1
2021	1	2	3
2022	0	3	3

Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.

Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S, Matrana MR, De Giorgi U, Rizzo M, Zabalza IO, Galli L, Zucali PA, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. Target Oncol. 2022 09; 17(5):571-581.

View in: PubMed
Lally DR, Hill L, Amador-Patarroyo MJ. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis. Ophthalmol Retina. 2022 11; 6(11):1054-1060.

View in: PubMed
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.

View in: PubMed
Foster WJ, Berg BW, Luminais SN, Hadayer A, Schaal S. Computational Modeling of Ophthalmic Procedures: Computational Modeling of Ophthalmic Procedures. Am J Ophthalmol. 2022 09; 241:87-107.

View in: PubMed
Cheng SY, Punzo C. Ocular Inflammation with Anti-Vascular Endothelial Growth Factor Treatments. Hum Gene Ther. 2021 Jul; 32(13-14):639-641.

View in: PubMed
Cheng SY, Luo Y, Malachi A, Ko J, Su Q, Xie J, Tian B, Lin H, Ke X, Zheng Q, Tai PWL, Gao G, Punzo C. Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis. Hum Gene Ther. 2021 07; 32(13-14):649-666.

View in: PubMed
Enr?quez AB, Baumal CR, Crane AM, Witkin AJ, Lally DR, Liang MC, Enr?quez JR, Eichenbaum DA. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021 Apr 01; 139(4):441-448.

View in: PubMed
Bressler NM, Beaulieu WT, Bressler SB, Glassman AR, Melia BM, Jampol LM, Jhaveri CD, Salehi-Had H, Velez G, Sun JK. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. Retina. 2020 Jun; 40(6):1021-1028.

View in: PubMed
Callahan R, Kieran MW, Baird CW, Colan SD, Gauvreau K, Ireland CM, Marshall AC, Sena LM, Vargas SO, Jenkins KJ. Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis. J Pediatr. 2018 07; 198:29-35.e5.

View in: PubMed
Ferrara D, Silver RE, Louzada RN, Novais EA, Collins GK, Seddon JM. Optical Coherence Tomography Features Preceding the Onset of Advanced Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017 07 01; 58(9):3519-3529.

View in: PubMed

People

Explore

Similar Concepts

Top Journals